Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Leases (2019 - 2026)

Corcept Therapeutics (CORT) has disclosed Current Leases for 8 consecutive years, with $1.6 million as the latest value for Q1 2026.

  • For Q1 2026, Current Leases rose 65.35% year-over-year to $1.6 million; the TTM value through Mar 2026 reached $1.6 million, up 65.35%, while the annual FY2025 figure was $1.1 million, 30.76% up from the prior year.
  • Current Leases hit $1.6 million in Q1 2026 for Corcept Therapeutics, up from $1.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.3 million in Q1 2022 and bottomed at $44000.0 in Q2 2024.
  • Average Current Leases over 5 years is $927588.2, with a median of $984000.0 recorded in 2025.
  • Year-over-year, Current Leases tumbled 86.88% in 2023 and then skyrocketed 2211.36% in 2025.
  • Corcept Therapeutics' Current Leases stood at $1.1 million in 2022, then tumbled by 86.79% to $151000.0 in 2023, then surged by 449.01% to $829000.0 in 2024, then surged by 30.76% to $1.1 million in 2025, then surged by 50.09% to $1.6 million in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $1.6 million, $1.1 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.